中国病理生理杂志2012，Vol.28Issue(5)：929-932,936,5.DOI:10.3969/j.issn.1000-4718.2012.05.029
ADRB2Gln27Glu基因多态性对经皮冠状动脉介入术后β受体阻滞剂临床疗效的影响
The influence of ADRB2 Gln27Glu genetic polymorphism on clinical effect of β-blocker therapy after percutaneous coronary intervention
摘要
Abstract
AIM: To explore the β - adrenergic receptor (ADRB2) Gln27Glu genelic polymorphism in pa-tients receiving β - blocker therapy after percutaneous coronary intervenion. METHODS; ADRB2 Gln27Glu genotypes were measured by TaqMan genotypingtLechnique in 384 palienls receiving β- blocker after percutaneous coronary inlerven-tion from Guangdong General Hospilal. RESULTS; Genotype frequencies accorded with Hardy - Weinberg equilibium ( P >0. 05). There was no significant difference in clinical characleristics among different genotypes (P>0. 05) and neilher was there in the kinds of β - blockers. Cox proportional hazards model demonslraled left main disease, diabeles and hyper-Lension were slrongly relaled wilh major adverse cardiac evenls ( MACE) [ relalive risk(RR) ;2. 661 (95% CI: 1.122-6. 307), 2.431 (95% CI:1.127-5.242) and 2. 98 (95% CI: 1.128-7.871), respec Lively; all P < 0. 05 ]. ADRB2 Gln27Glu genetic polymorphism was not relaled Lo MACE (RR:1.408, 95% CI: 0.650 -3. 053 ,P >0. 05) . CONCLUSION; ADRB2 Gln27Glu genetic polymorphism was not relaled to the clinical effect of β -blocker iherapy afler perculaneous coronary inlervenlion.关键词
受体,肾上腺素能,β2/基因多态性/经皮冠状动脉介入术/β受体阻滞剂,肾上腺素能/主要心脏不良事件Key words
Receplors, adrenergic, beta - 2/ Genelic polymorphism/ Perculaneous coronary inlervenlion/ β-Blockers, adrenergic/ Major adverse cardiac evenls分类
医药卫生引用本文复制引用
杨大浩,钟诗龙,陈纪言,余细勇,郑志伟,刘远辉,何鹏程,温剑艺,谭宁..ADRB2Gln27Glu基因多态性对经皮冠状动脉介入术后β受体阻滞剂临床疗效的影响[J].中国病理生理杂志,2012,28(5):929-932,936,5.基金项目
国家自然科学基金资助项目(No.81072701) （No.81072701）
广东省自然科学基金资助项目(No.10151008002000002 （）
No.S2011010005830) （）
